(Q34389584)

1 August 2017

1 reference

title

Treatment of the elderly with 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors: focus on drug interactions (English)

1 reference

1 August 2017

M H Davidson

1

1 reference

1 August 2017

publication date

1 July 2001

1 reference

Journal of Cardiovascular Pharmacology and Therapeutics

1 August 2017

published in

1 reference

1 August 2017

volume

6

1 reference

1 August 2017

issue

3

1 reference

1 August 2017

page(s)

219-229

1 reference

Time Trends in the Use of Cholesterol-Lowering Agents in Older Adults

1 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1177%2F107424840100600302

Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107424840100600302

Prediction of Coronary Heart Disease Using Risk Factor Categories

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107424840100600302

The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107424840100600302

Effect of pravastatin on cardiovascular events in older patients with myocardial infarction and cholesterol levels in the average range. Results of the Cholesterol and Recurrent Events (CARE) trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107424840100600302

Prevention of Cardiovascular Events and Death with Pravastatin in Patients with Coronary Heart Disease and a Broad Range of Initial Cholesterol Levels

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107424840100600302

Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107424840100600302

Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107424840100600302

Serum cholesterol levels and six-year mortality from stroke in 350,977 men screened for the multiple risk factor intervention trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107424840100600302

Cholesterol lowering with statin drugs, risk of stroke, and total mortality. An overview of randomized trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107424840100600302

Treating patients with documented atherosclerosis to National Cholesterol Education Program-recommended low-density-lipoprotein cholesterol goals with atorvastatin, fluvastatin, lovastatin and simvastatin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107424840100600302

MRC/BHF Heart Protection Study of cholesterol-lowering therapy and of antioxidant vitamin supplementation in a wide range of patients at increased risk of coronary heart disease death: early safety and efficacy experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107424840100600302

Cost-effectiveness of HMG-CoA reductase inhibition for primary and secondary prevention of coronary heart disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107424840100600302

Cost-effectiveness of 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors in the secondary prevention of cardiovascular disease: forecasting the incremental benefits of preventing coronary and cerebrovascular events

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107424840100600302

Rhabdomyolysis and renal injury with lovastatin use. Report of two cases in cardiac transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107424840100600302

Grapefruit juice-simvastatin interaction: effect on serum concentrations of simvastatin, simvastatin acid, and HMG-CoA reductase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107424840100600302

Epidemiology of adverse drug reactions in the elderly by drug class

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107424840100600302

Recent Advances: the Cytochrome P450 Enzymes

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107424840100600302

Low-dose simvastatin for the treatment of hypercholesterolaemia in recipients of cardiac transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107424840100600302

Fluvastatin in combination with cyclosporin in renal transplant recipients: a review of clinical and safety experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107424840100600302

Does differing metabolism by cytochrome p450 have clinical importance?

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107424840100600302

Clinical pharmacokinetics of fibric acid derivatives (fibrates).

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107424840100600302

Rhabdomyolysis and renal failure associated with cerivastatin-gemfibrozil combination therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107424840100600302

Different effects of itraconazole on the pharmacokinetics of fluvastatin and lovastatin

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107424840100600302

Simvastatin but not pravastatin is very susceptible to interaction with the CYP3A4 inhibitor itraconazole.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107424840100600302

Newer antidepressants and the cytochrome P450 system

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107424840100600302

Hyperlipidemia associated with HIV protease inhibitor use: pathophysiology, prevalence, risk factors and treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107424840100600302

Grapefruit juice increases serum concentrations of atorvastatin and has no effect on pravastatin

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107424840100600302

The design of a prospective study of pravastatin in the elderly at risk (PROSPER)

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107424840100600302

10.1177/107424840100600302

21 January 2018

Identifiers

DOI

1 reference

1 August 2017

1 reference